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Introduction
Randomized clinical trials of aggressive non-Hodgkin lym-
phoma (NHL), including diffuse large B-cell lymphoma
(DLBCL), mantle cell lymphoma (MCL) and Burkitt lym-
phoma (BL), show considerable improvement in clinical out-
come over the last two decades. First, the introduction in
1997 of the monoclonal antibody targeting CD20, rituximab,
increased overall survival (OS).1-4 Second, the introduction of
more intensive therapy in first-line treatment, including autol-
ogous stem cell transplantation (ASCT), improved OS of
MCL and BL.5-9
However, only a small selection of patients taken from the
entire patient population typically takes part in randomized
clinical trials. Particularly patients with comorbidities and
age-related organ dysfunction are under-represented in clini-
cal trials.10 Moreover, patients aged 80 years or older are often
excluded from trials.3,11 This situation highlights the impor-
tance of population-based registries that provide the opportu-
nity to determine whether new treatment options are imple-
mented and whether this is beneficial in an unselected patient
population, including elderly patients or patients with
marked comorbidity. 
Several existing population-based registries on the clinical
outcome in aggressive B-cell lymphoma show an improve-
ment in survival.12-14 However, this is the first large popula-
tion-based study with separate analyses of specific patholog-
ical subtypes of aggressive B-cell lymphoma in different age
groups, with regard to incidence and survival over time.
Methods
Study population and data collection
The Netherlands Cancer Registry (NCR) started in 1989 and is
based on notification of all newly diagnosed malignancies in the
Netherlands by the automated national pathological archive PALGA.
Information on patients’ characteristics, tumor characteristics, and pri-
mary treatment are routinely obtained from medical records.
Information on the date of death (date of last follow up: February
1st, 2013) was actively obtained from the municipal registries (GBA)
and from the database of deceased persons of the Central Bureau for
Genealogy. Survival time was calculated as time from date of diagno-
sis to date of death, date of emigration or to February 1st, 2013.
For the present study, all newly diagnosed patients over 15 years of
age were selected with DLBCL (ICD-O-3 morphology codes: 9680,
9684, 9675, 9679, 9591, 9590; ICD-O-2: 9593, 9677, 9681, 9682, 9712),
BL (ICD-O-3: 9687, 9826) in the period 1989-2010, and MCL (ICD-O-
3: 9673) in the period 2001-2010 (from 2001, MCL was a separate
diagnosis).
As the survival pattern (a high number of deaths in the first year
after diagnosis) of unspecified NHL was roughly the same as for
DLBCL or BL, unspecified NHL (decreasing from 18% in the period
1989-1993 to 6% in the period 2005-2010) was considered as aggres-
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Only a small number of patients with aggressive B-cell lymphoma take part in clinical trials, and elderly patients
in particular are under-represented. Therefore, we studied data of the population-based nationwide Netherlands
Cancer Registry to determine trends in incidence, treatment and survival in an unselected patient population. We
included all patients aged 15 years and older with newly diagnosed diffuse large B-cell lymphoma or Burkitt lym-
phoma in the period 1989-2010 and mantle cell lymphoma in the period 2001-2010, with follow up until February
2013. We examined incidence, first-line treatment and survival. We calculated annual percentage of change in inci-
dence and carried out relative survival analyses. Incidence remained stable for diffuse large B-cell lymphoma
(n=23,527), while for mantle cell lymphoma (n=1,634) and Burkitt lymphoma (n=724) incidence increased for men
and remained stable for women. No increase in survival for patients with aggressive B-cell lymphoma was
observed during the period 1989-1993 and the period 1994-1998 [5-year relative survival 42% (95%CI: 39%-45%)
and 41% (38%-44%), respectively], but increased to 46% (43%-48%) in the period 1999-2004 and to 58% (56%-
61%) in the period 2005-2010. The increase in survival was most prominent in patients under 65 years of age,
while there was a smaller increase in patients over 75 years of age. However, when untreated patients were exclud-
ed, patients over 75 years of age had a similar increase in survival to younger patients. In the Netherlands, survival
for patients with aggressive B-cell lymphoma increased over time, particularly in younger patients, but also in eld-
erly patients when treatment had been initiated. The improvement in survival coincided with the introduction of
rituximab therapy and stem cell transplantation into clinical practice.
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sive lymphoma and classified as DLBCL (since 84% of aggressive
lymphoma is DLBCL) for the incidence analyses. This was done
to minimize the effect of changes in classification on outcome of
trends analyses of incidence. For the survival analyses, we exclud-
ed the unspecified cases. 
Year of diagnosis was divided into four periods for DLBCL and
BL: 1989-1993, 1994-1998, 1999-2004, and 2005-2010, and into
two periods for MCL: 2001-2004 and 2005-2010.
Treatment
Primary treatment was described as percentage of patients who
received chemotherapy alone, radiotherapy alone, chemothera-
py+radiotherapy, transplantation (+/-radiotherapy/chemothera-
py), other therapies, no therapy, and unknown therapy, for sub-
group, stage, age group and period. Complete data on the use of
immunotherapy have been registered by the NCR since 2007.
Statistical analyses
Annual incidence rates according to sex for the period 1989-
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Table 1. Patients’ characteristics of aggressive B-cell lymphoma,
according to subgroup, in the Netherlands, 1989-2010.
DLBCL MCL BL
N 23527 1634 724
Mean age (range)(yr) 66 (15-103) 71 (28-93) 49 (15-93)
Age (%) 15-39 7 2 35
40-64 33 33 37
65-74 26 33 14
>75 34 32 14
Male sex (%) 53 74 66
Stage (%) I 27 6 18
II 20 9 13
III 16 13 9
IV 30 70 55
Unknown 7 2 5
DLBCL: diffuse large B-cell lymphoma; MCL: mantle cell lymphoma; BL: Burkitt lym-
phoma. 
Table 2. Overview of clinical trials of aggressive B-cell lymphoma; OS compared with outcome in the Netherlands. 
Study Regimen Median age/Patients OS (%) Median Patients OS (%) Patients OS (%)
range number CI (%) age/range number CI (%) number CI (%)
2001-2010; 2001-2010;
Clinical studies Our study all cases only CT cases
DLBCL
Pfreundschuh et al.3 6 CHOP14 68 (61-80) 1,222 68 (62-74) at 3 yrs 72 (61-80) 5,408 54 (53-55) 4,504 61 (60-63)
8 CHOP14 66 (60-72) at 3 yrs at 3 yrs at 3 yrs
6 R-CHOP14 78 (73-83) at 3 yrs
8 R-CHOP14 73 (67-78) at 3 yrs 
Feugier et al. (2005)11 R-CHOP21 69 (60-80) 399 58 (51-65) at 5 yrs 71 (60-80) 5,610 46 (45-48) 4,684 53 (51-54)
Coiffier et al. (2010)15 CHOP21 45 (39-53) at 5 yrs at 5 yrs at 5 yrs
44 (36-54) at 10 yrs 30 (29-33) 35 (33-37)
28 (21-34) at 10 yrs at 10 yrs at 10 yrs
Pfreundschuh et al.16 R-CHOP like 47 (35-55) 823 90 (86-93) at 6 yrs 48 (35-55) 1,954 71 (69-73) 1,848 73 (71-75)
CHOP like 80 (75-84) at 6 yrs at 6 yrs at 6 yrs
Ohmachi et al.17 CHOP14 57 (17-69) 323 55 (47-63) at 8 yrs 58 5,566 60 (59-62) 5,158 63 (61-64)
CHOP21 56 (47-64 at 8 yrs (17-69) at 8 yrs at 8 yrs
Recher et al.18 R-ACVBP 48 (18-59) 379 92 (87-95) at 3 yrs 49 3,209 75 (74-77) 3,025 77 (76-79)
R-CHOP 84 (77-89) at 3 yrs (18-59) at 3 yrs at 3 yrs
Peyrade et al.19 6 R-miniCHOP 83 (80-95) 150 59 (49-67) at 2 yrs 84 2,134 30 (28-32) 1,030 45 (42-48)
(80-95) at 2 yrs at 2 yrs
Cunningham et al.20 6R-CHOP14 + 2R 61 (19-88) 1080 83 (80-86) at 2 yrs 69 (19-88) 10,323 60 (59-61) 8,453 69 (68-70) 
8 R-CHOP21 81 (78-84) at 2 yrs at 2 yrs at 2 yrs
Delarue et al.21 8 R-CHOP14 70 (59-80) 602 69 (64-72) at 3 yrs 71 (59-80) 5,805 55 (54-56) 4,860 62 (61-64) 
8 R-CHOP21 72 (67-77) at 3 yrs at 3 yrs at 3 yrs
MCL
Van ‘t Veer  et al.22 R-CHOP, HD Ara-C, 55 (32-66) 87 79 at 4 yrs 58 (32-66) 602 62 (58-66) 536 62 (58-66)
BEAM-ASCT at 4 yrs at 4 yrs
Damon et al. 23 R-M-CHOP+ 57 (37-69) 79 64 at 5 yrs 61 (37-69) 738 54 (50-58) 650 54 (49-58) 
EAR+CBV-ASCT at 5 yrs at 5 yrs
Gressin et al.24 8VAD+C > 60 (61-75) 35 51 at 3 yrs 69 (61-75) 747 52 (48-55)  at 3 yrs 621 52 (48-56) at 3 yrs
6(R)VAD+C+ASCT < 65 (18-64) 78 67 at 3 yrs 57 (18-64) 517 72 (68-76) at 3 yrs 462 73 (68-77) at 3 yrs
Romaguera et al.25 R-HCVAD-AM 61 (41-80) 97 56 at 8 yrs 69 (41-80) 1,366 29 (26-32) at 8 yrs 1,123 29 (26-32)at 8 yrs
Age ≤65 years 65 68 at 8 yrs ≤65 47 (42-52) at 8 yrs ≤65 47 (41-52) at 8 yrs
Age >65 years 32 33 at 8 yrs >65 17 (14-20) at 8 yrs >65 16 (13-20) at 8 yrs
Merli et al.26 R-HCVAD-AM 57 (22-66) 60 73 (59-83) at 5 yrs 58 (22-66) 603 58 (53-62) at 5 yrs 536 57 (53-61) at 5 yrs
Geisler et al.8 R-maxiCHOP+R- 56 (32-65) 160 66 at 6 yrs 58 (32-65) 557 50 (45-54) at 6 yrs 495 49 (44-54) at 6 yrs
to be continued on next page.
2010 were calculated per 100,000 person-years, using the annual
mid-year population size as obtained from Statistics Netherlands.
Rates were age standardized to the European standard population
(ASR). Incidence rates were also calculated per age group. Trends
in incidence were evaluated by calculating the estimated annual
percentage change (EAPC) and the corresponding 95% confidence
interval (95%CI). 
Relative survival (RS), which can be interpreted as disease-spe-
cific survival within a cancer patient population (independent of
the cause of death), was estimated as ratio of the observed survival
of cancer patients and the expected survival of a comparable age-
and sex-matched group of the general population. 
In order to compare results with those from recent clinical stud-
ies we also calculated OS. For each phase II or III study with a min-
imum number of cases (DLBCL 140, MCL 60, BL no minimum)
published since 2008 (DLBCL, MCL) or 2005 (BL), we selected
patients from the NCR with the same age range and same diagno-
sis as patients in the equivalent trial. OS was calculated for all
patients as well as for patients receiving chemotherapy with the
same age range and diagnosis for the period 2001-2010. 
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Geisler et al.27 HD Ara- 58 at 10 yrs 37 (30-43) at 10 yrs 36 (29-43) at 10 yrs
C+BEAM/BEAC- ASCT
Raty et al.28 74 (65-83) 60 72 at 4 yrs 74 (65-83) 980 34 (31-37) at 4 yrs 786 34 (30-37) at 4 yrs
Kluin-Nelemans et al.29 R-FC 70 (60-83) 560 47 at 4 yrs 72 (60-83) 1,157 38 (35-41) at 4 yrs 906 38 (35-41) at 4 yrs
R-CHOP 62 at 4 yrs
R-CHOP+ MT R 87 at 4 yrs
R-CHOP+ inta   63 at 4 yrs
Delarue et al.5 CHOP, DHAP +R, 57 (40-66) 60 75 at 5 yrs 59 (40-66) 589 57 (53-61) at 5 yrs 526 56 (52-61) at 5 yrs
BEAM-ASCT BL
BL
Divine et al.30 LMB protocol 33 (18-76) 72 70 at 2 yrs 46 (18-76) 332 51 (46-57) at 2 yrs 291 57 (61-63) at 2 yrs
Age <33 years 37 84 at 2 yrs <33 73 (61-81) at 2 yrs <33 74 (62-82) at 2 yrs
Age ≥33 years 35 60 at 2 yrs ≥33 46 (39-51) at 2 yrs ≥33 52 (45-58) at 2 yrs
Van Imhoff et al.9 HD sequential 36 (15-64) 27 81 at 5 yrs 41 (15-64) 274 57 (51-63) at 5 yrs 257 59 (53-65) at 5 yrs
CT+ ASCT
Thomas et al.4 R-Hyper-CVAD 46 (27-77) 31 89 at 3 yrs 50 (27-77) 291 46 (40-52) at 3 yrs 248 52 (46-58) at 3 yrs
Age < 60 years 22 90 at 3 yrs <60 56 (48-63) at 3 yrs <60 58 (50-65) at 3 yrs
Age ≥ 60 years 9 89 at 3 yrs ≥60 28 (19-37) at 3 yrs ≥60 39 (28-50) at 3 yrs
Hoelzer et al.31 GMALL B-ALL/NHL 15-55 115 91 at 3 yrs 38 (15-55) 228 64 (57-70) at 3 yrs 214 66 (60-72) at 3 yrs
≥ 55 (56-78) 36 84 at 3 yrs 68 (56-78) 128 30 (23-39) at 3 yrs 96 41 (31-50) at 3 yrs
Mead et al.32 dm CODOX-M/IVAC 37 (17-76) 53 67 (54-80) at 2 yrs 45 (17-76) 334 52 (46-57) at 2 yrs 293 58 (52-63) at 2 yrs
Oriol et al.33 GMALL B-ALL/NHL 36 (15-55) 36 77 (64-90) at 2 yrs 38 (15-55) 228 64 (58-70) at 2 yrs 214 67 (60-73) at 2 yrs
Rizzieri et al.34 CALGB 10002 (19-79) 105 79 at 2 yrs 47 (19-79) 342 50 (44-55) at 2 yrs 291 57 (51-62) at 2 yrs
Dunleavy et al35 DA-EPOCH-R 35 (16-88) 30 82 at 4 yrs 49 (16-88) 376 47 (42-52) at 4 yrs 311 55 (49-60) at 4 yrs
Corazzelli et al.36 dm CODOX-M/IVAC 52 (25-77) 30 82 at 4 yrs 50 (25-77) 293 45 (39-51) at 4 yrs 249 52 (45-58) at 4 yrs
age <60 years 18
age ≥60 years 12
Hoelzer et al.37 Short-intensive CT 363 371 309
B-NHL 40 (16-79) 88 at >7 yrs 46  (16-79) 52 (46-58) at 7 yrs 59 (52-65)  at 7 yrs
Age 15-≤25 years 91 at >7 yrs 83 (67-91) at 7 yrs 85 (69-93)  at 7 yrs
Age 26-55 years 91 at >7 yrs 60 (52-68) at 7 yrs 63 (54-70)  at 7 yrs
Age >55 years 80 at >7 yrs 28 (19-38) at 7 yrs 38 (26-50)  at 7 yrs
B-L 47 (16-85) 53  (18-82)
Age 15-≤25 years 90 at >7 yrs 70 (33-89) at 7 yrs 70 (33-89)  at 7 yrs
Age 26-55 years 71 at >7 yrs 36 (18-54) at 7 yrs 37 (19-55)  at 7 yrs
Age >55 years 46 at >7 yrs 9 (2-22) at 7 yrs 13 (3-30)  at 7 yrs
Kasamon et al.38 BASIC therapy 53 (34-75) 21 57 (40-83) at 3 yrs 52 (34-75) 242 44 (37-50) at 3 yrs 207 50 (43-56) at 3 yrs
OS: overall survival; yrs, years; CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednison; R: rituximab; R-ACVBP: rituximab, doxorubicin, cyclophosphamide, vinde-
sine, bleomycin, prednisone; HD Ara-C: high dose cytarabine; BEAM: carmustine, etoposide, Ara-C, melphalan; ASCT: autologous stem cell transplantation; M: methotrexate; EAR:
etoposide, cytarabine, rituximab; CBV: carmustine, etoposide, cyclophosphamide; VAD: vincristine, doxorubicine, dexamethasone; C: chlorambucil;R-HCVAD-AM: rituximab-hyperfrac-
tionated cyclophosphamide, vincristine, doxorubicin, dexamethasone)-high dose cytararabine, methotrexate; MT: maintenance therapy; F: fludarabine; FC: fludarabine, cyclophos-
famide;  int a, interferon alfa; DHAP: dexamethasone, high-dose cytarabine, cisplatin; HD: high dose; CT: chemotherapy; dm CODOX-M/IVAC: dose-modified cyclophosphamide,
cytarabine, doxorubicin, leucovorin, methotrexate, vincristine/cytarabine, etoposide, ifosfamide, methotrexate; DA-EPOCH-R; B-NHL: Burkitt Non-Hodgkin lymphoma; B-L: Burkitt
leukemia; BASIC: brief, anthracycline-sparing, intensive cyclophosphamide.
Table 2. (continued from previous page)
Study Regimen Median age/Patients OS (%) Median Patients OS (%) Patients OS (%)
range number CI (%) age/range number CI (%) number CI (%)
2001-2010; 2001-2010;
Clinical studies Our study all cases only CT cases
Statistical analyses were carried out using SAS software (SAS
system 9.2; SAS Institute, Cary, NC, USA).
Results
Demographic data
Table 1 shows the demographic data of patients with
newly diagnosed DLBCL, MCL and BL in the Netherlands
during the period 1989-2010. Mean age of patients with
Burkitt lymphoma was considerably lower than DLBCL
and MCL (49, 66 and 71 years, respectively). There was a
strong male predominance for MCL and BL, 74% and
66%, respectively, which was not observed in DLBCL
patients (53%). Stage IV disease was more pronounced in
MCL and BL (70 and 55%, respectively) versus 30% in
DLBCL. 
Trends in incidence 
Age-standardized incidence (ASR) per 100,000 person-
years remained stable for DLBCL (7.7 in 1989, 7.6 in 2010
for men (EAPC -0.3%, 95%CI: -0.4-0.1%), and 5.2 in 1989
[5.0 in 2010 for women (EAPC -0.4%, 95%CI: -0.7- -
0.1%)] (Figure 1). Little change was observed in age-specif-
ic rates (Figure 2A).
For patients with MCL, there was no significant change
in ASR between 2001 and 2010, in males (ASR 1.3 in 2001
and 1.4 in 2010) or in females (ASR 0.4 in 2001 and in
2010) (Figure 1). Stratified by age, we found a large
increase in MCL patients over 75 years of age (EAPC
males +5.4%, 95%CI: 1.3%-9.6%; females +8.3%
95%CI: -2.1%-20%). However, the increase was statisti-
cally significant in males only (Figure 2B).
The ASR of BL increased from 0.2 in 1989 to 0.4 in 2010
for men (EAPC 3.2%, 95%CI: 1.6-4.7) and remained sta-
ble for women [0.1 in 1989 and 2010 (EAPC 1.4%, 95%CI:
-1.4-4.2)].
Trends in first-line treatment
DLBCL: the majority of patients with DLBCL (56%)
received “chemotherapy alone”, in particular for stage II,
III and IV. The percentage of patients with stage I who
received  “radiotherapy alone” decreased over time (from
33% to 10%), whereas the percentage of patients who
received combination “chemotherapy plus radiotherapy”
increased (from 18% to 37%) (Figure 3A).
A considerable proportion of elderly patients did not
receive any treatment (17% in patients 65-74 years of age
and 36% in patients ≥75 years, vs. only 10% in patients
<65 years).
Data on treatment with rituximab have been available
since 2007. The percentage of patients receiving
immunochemotherapy rose from 83% in 2007 to 97% in
2010, independent of age. 
Furthermore, patients with DLBCL were generally not
treated with stem cell transplantation as first-line treat-
ment.
MCL: the majority of patients with MCL (62%) received
“chemotherapy alone”, in particular for stage II, III and IV. 
A considerable proportion of elderly patients did not
receive any treatment (16% in patients 65-74 and 34% in
patients ≥75 years vs. only 10% in patients <65 years).
During 2007-2010, the percentage of patients treated
with rituximab (in combination with chemotherapy) rose
over time, from 68% in 2007 to 90% in 2010. However,
the proportion of patients treated with rituximab in 2010
was considerably higher in patients aged under 65 years of
years and aged 65-74 years, (98% and 94%, respectively)
than in patients over 75 years of age (78%; χ2 test:
P=0.004). Moreover, stem cell transplantation was admin-
istered more to patients with MCL under 65 years of age,
rising from 18% in the period 2001-2004 to 50% in the
period 2005-2010 (Figure 3B).
BL: the majority of patients with BL (61%) received
“chemotherapy alone” without any distinction in stage
(Figure 3C). The percentage of patients receiving no treat-
ment was considerably higher in patients aged > 65 years
than in patients aged 40-64 years and <40 years (38%,
10% and 4%, respectively). The percentage of patients
treated with rituximab (in combination with chemothera-
py) rose over time, from 65% in 2007 to 88% in 2010,
independent of age. 
Furthermore, the percentage of patients with BL under
65 years of age receiving stem cell transplantation,
increased from 5% in the period 1989-1993 to 18% in the
period 2005-2010. 
Trends in survival
In the first ten years of the study period (1989-1998), no
increase in survival of aggressive B-cell lymphoma was
observed [5-year RS 42% (95%CI: 39%-45%) and 41%
(95%CI: 38%-44%) in 1989-1993 and 1994-1998, respec-
tively]. After 1998, relative survival rose [5-year RS 46%
(95%CI: 43-48%) in 1999-2004], particularly since 2005
(5-year RS 58%, 95%CI: 56%-61%). 
DLBCL: the 5-year RS for patients with DLBCL under
65 years of age increased remarkably with 28%, from
57% (95%CI: 54%-59%) in the period 1989-1993 to 75%
(95%CI: 73%-77%) in the period 2005-2010. Relative sur-
vival for patients aged 65-74 years rose by 22%, from 40%
(95%CI: 36%-43%) in the period 1989-1993 to 62%
(95%CI: 59%-64%) in the period 2005-2010. For patients
over 75 years of age, survival increased by 13%, from 28%
(95%CI: 24-32%) in the period 1989-1993 to 41% (95%
CI 38-44%) in the period 2005-2010 (Figure 4A). After
exclusion of untreated patients, results for patients under
75 years of age were the same. However, patients over 75
years of age showed a remarkable rise in survival of 20%,
from 33% (95%CI: 29-38%) in the period 1989-1993 to
53% (95%CI: 49%-57%) in 2005-2010 (data not shown).
Sex did not significantly affect these results. Furthermore,
as expected, outcome deteriorated with increased disease
stage, with a 5-year RS ranging from 72% for stage I to
42% for stage IV in the period 2005-2010.
MCL: the 5-year RS for patients with MCL aged under
65 years of age increased remarkably (by 20%), from 52%
(95%CI: 44%-60%) in the period 2001-2004 to 72%
(95%CI: 66%-77%) in the period 2005-2010. 
The RS increased with 18% for patients 65-74 years,
from 24% (95%CI: 19%-30%) in the period 2001-2004 to
42% (95%CI: 36%-49%) in the period 2005-2010. For
patients over 75 years of age the survival increased with
11%, from 17% (95%CI: 11%-23%) to 28% (95%CI:
22%-35%). 
The difference in 5-year survival for all patients with
MCL under 65 years of age treated with and without a
stem cell transplantation was significant, 77% and 48%
respectively (P<0.0001) (data not shown). No difference in
survival was observed when untreated patients were
excluded. Sex did not significantly affect these results. 
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Furthermore, outcome was inferior with increased dis-
ease stage, with a 5-year RS ranging from 67% for stage I
to 41% for stage IV in the period 2005-2010.
BL: for patients with BL under 40 years of age, 5-year RS
increased by 30%, from 44% (95%CI: 28%-58%) in the
period 1989-1993 to 74% (95%CI: 63%-82%) in the peri-
od 2005-2010. The survival for patients aged 40-64 years
rose by 16%, from 32% (95%CI: 18%-47%)  in 1989-
1993 to 48% (95%CI: 37%-58%) in the period 2005-2010.
Relative survival for patients over 65 years of age
increased by less than 10%, from 18% (95%CI: 6%-38%)
in the period 1989-1993 to 28% (95%CI: 17%-41%) in the
period 2005-2010 (Figure 4C). When untreated patients
were excluded, the results for patients under 65 years of
age were the same, in contrast to patients over 65 years of
age who showed a rise in survival of 15%, from 26%
(95%CI: 8%-51%) in the period 1989-1993 to 41%
(95%CI: 25%-59%) in the period 2005-2010 (data not
shown). However, these data were not statistically signifi-
cant. Sex did not significantly affect these results.  
Table 2 shows a comparison of OS from our study with
that reported in recent clinical trials, with the same age
range and same diagnosis as patients in the equivalent
trial. Our study showed inferior survival rates for patients
with DLBCL, MCL and BL, even when untreated patients
were excluded.
Discussion
Our population-based registry showed similar incidence
rates to those found in other studies conducted in Europe,
in particular, a similar increase in incidence of male
patients with MCL and BL.39-41 The causes for male pre-
dominance in MCL and BL are still unknown.42-44
Furthermore, our study showed a pronounced improve-
ment in survival for patients with aggressive B-cell lym-
phoma, particularly during the last decade. Although the
improvement in survival was observed independent of
age, the outcome was significantly inferior in the elderly
patients, especially in patients over 75 years of age.
Compared with previous population-based studies in
Europe and the United States, our study showed similar
RS for patients with aggressive B-cell lymphoma.45-48 For
example, in the period 1973-2003, the SEER (Surveillance,
Epidemiology and End Results) database showed a RS of
48% for DLBCL, 53% for MCL and 45% for BL.47 In the
period 2000-2002, the European database showed an RS
of 49% for DLBCL, 44% for MCL and 56% for BL.45 The
Swedish Lymphoma Registry showed a similar improve-
ment in survival for MCL: an increase in 3-year OS from
47% in the period 2000-2005 to 62% in the period 2006-
2010.49 However, compared with clinical trials, our study
showed inferior survival rates for patients with DLBCL,
MCL and BL, even when the same age range was ana-
lyzed and when untreated patients were excluded (Table
2). The discrepancy in survival in patients under and
patients over 65 years of age was comparable among clin-
ical trials and our study. 
As our population-based data are not randomized, com-
parison of DLBCL treated with CHOP with or without rit-
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Figure 1. (A). Age-standardized incidence rate (ASR) of diffuse large
B-cell lymphoma (DLBCL), according to subgroup and sex, in the
Netherlands, 1989-2010. (B). Age-standardized incidence rate (ASR)
of mantle cell lymphoma (MCL), according to subgroup and sex, in
the Netherlands, 2001-2010. (C). Age-standardized incidence rate
(ASR) of BL, according to subgroup and sex, in the Netherlands,
1989-2010. 
Figure 2. (A). Age-standardized incidence rate (ASR) of diffuse large
B-cell lymphoma (DLBCL), by sex and age, in the Netherlands, 1989-
2010. (B). Age-standardized incidence rate (ASR) of mantle cell lym-






























































































































































uximab should be interpreted with caution. However, as
expected, stratified by age group, we found an absolute
difference in 5-year survival of approximately 20% in
favor of rituximab. Bias in patient selection is likely to
have contributed to this large difference.
There are several explanations for the difference in sur-
vival between young and elderly patients and the inferior
outcome in our study compared with clinical trials. First,
only a small, selected proportion of the entire patient pop-
ulation takes part in trials; in particular, elderly patients
and those with serious comorbidity are under-represent-
ed50,51 and patients aged 80 years or older are often exclud-
ed. 5,15,52-54 Since age is a strong adverse prognostic factor in
aggressive B-cell lymphoma, exclusion of elderly patients
results in higher survival rates in trials.10,55,56 For example,
Advani showed that patients aged 70 years or over were
at increased risk of failure compared to patients under 70
years of age, with a 3-year OS of 58% [95%CI: (49, 66)]
and 74% [95%CI: (72, 82)], respectively.56 Furthermore,
comorbidity has been found to be related to age. In the
study of Janssen-Heijnen, 79% of patients over 60 years of
age diagnosed with NHL had serious comorbidity in con-
trast to only 48% for patients under 60 years of age.57
Besides, in the presence of comorbidity, the percentage of
patients receiving chemotherapy declined, especially
among elderly patients.58 This is supported by the signifi-
cantly higher proportion of elderly patients in our study
compared to clinical trials, with a mean age of 66 years in
our study versus 61 years in the study of Cunningham.20 A
considerable number of the elderly patients in our study
did not receive any treatment and consequently they had
a low survival rate. However, even after correcting for
non-treatment, survival remains inferior when compared
with clinical trials. 
Differences in therapy could be a second reason. For
example, rituximab came into use in the USA in 1997 and
in Europe in 2000, albeit not simultaneously in all coun-
tries.59,60 This is reflected by the consistently observed
higher OS in the rituximab treated patients in the random-
ized clinical trials, as described in Table 2. Besides, in gen-
eral a delay in the introduction of new agents is observed
in the elderly population with comorbidity. For example,
elderly patients with MCL in our study received less treat-
ment with rituximab than younger patients.
A further explanation is that, in general, elderly patients
did not receive intensive chemotherapy combined with
autologous stem cell transplantation, whereas a high per-
centage of the younger patients did. In our study, this is
seen in particular for MCL patients: patients under 65
years of age were treated with a stem cell transplantation
in 50% of the cases compared with 1% in patients over 65
years of age.
Several studies have reported that elderly patients, aged
up to 80 years, are able to tolerate full-dose R-CHOP reg-
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Figure 3. (A). Trends in primary treatment for
diffuse large B-cell lymphoma (DLBCL),
according to period, stage and age, in the
Netherlands, 1989-2010. (B). Trends in pri-
mary treatment for mantle cell lymphoma
(MCL), according to period, stage and age, in
the Netherlands, 2001-2010. (C). Trends in
primary treatment for Burkitt lymphoma
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imens.3,5,20 Although approximately one-third of the cases
of NHL occur in patients older than 75 years, few data are
available concerning the optimal treatment in this age
group. It has been assumed that many older patients are
too frail to receive standard therapy.10,61 Peyrade showed in
very elderly patients aged over 80 years, that addition of
rituximab to 50%-reduced CHOP seems to be a good
compromise between toxicity and efficacy, with a 2-year
OS of 59%.19 Although no precise data on the dose of ther-
apy are available, also in our study, good results were
observed for elderly patients receiving treatment , with a
2-year OS of 45% for cases diagnosed in the period 2001-
2010. 
This study has several limitations, which must be con-
sidered when interpreting our results. 
First, the classification of aggressive lymphoma has
changed considerably over time, with a decrease in the
number of unspecified cases. These unspecified cases
might have been incorrectly diagnosed as DLBCL, as this
is by far the largest diagnostic group of the aggressive lym-
phomas. Part of the unspecified cases may actually have
been MCL, BL or indolent lymphoma. However, the
equivalent survival curves of unspecified and aggressive
lymphoma support our classification strategy, with only a
1% difference in survival between both groups, implying
that this percentage does not generally affect the analyses.
Second, the classification criteria for BL have changed
over time, which may have influenced the results for BL.
Moreover, during the period 1989-1992, Burkitt leukemia
could not be included as in that period no separate mor-
phology code was available in the International
Classification of Diseases for Oncology (ICD-O).
Consequently, the observed incidence rate for BL during
the period 1989-1992 is slightly under-estimated.
Third, despite the rather clinical nature of the Dutch
cancer registries, the lack of detailed information regarding
exact treatments, comorbidities and dose adherence in our
population-based registry has limited the possibility of
exploring and clarifying specific reasons for the observed
changes in survival.
In conclusion, in the Netherlands, survival for newly
diagnosed patients with aggressive B-cell lymphoma has
increased over time, particularly in patients under 65 years
of age. However, even though survival of elderly patients
was inferior in comparison with survival of younger
patients, a similar increase in survival occurred when treat-
ment was initiated.
The main contributors to the improvement in survival in
our study and clinical trials appear to be rituximab thera-
py,1-4,31,59,62,63 autologous stem cell transplantation, and the
use of more intensive chemotherapy.5-9,22,64,65 
The therapeutic goal in treating elderly NHL patients
must be to maintain a balance between effective therapy
and treatment toxicity. As patients over 65 years consti-
tute around two- thirds of all patients with aggressive
lymphoma, clinical trials for elderly ‘frail’ patients with no
barrier for comorbidity are needed to determine appropri-
ate therapy for these patients. Comprehensive geriatric
assessment (CGA) could be used for additional informa-
tion.66,67
Since it is important to have more detailed information
regarding exact treatments, dose adherence and comor-
bidities for a better understanding of the treatment and
outcome of patients with hematologic malignancies, an
extensive registry was initiated in the Netherlands, supple-
mentary to the cancer registry. This PHAROS registry
(Population-based Haematological Registry for
Observational Studies) is expected to supply more
detailed data in the near future.
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Figure 4. (A). Trends in 5-year relative survival for diffuse large B-cell
lymphoma (DLBCL) according to age and period, in the Netherlands,
1989-2010. (B). Trends in 5-year relative survival for MCL according
to age and period, in the Netherlands, 2001-2010. (C). Trends in 5-
year relative survival for diffuse large B-cell lymphoma (DLBCL)
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